אקסיטיניב טבע  3 מג イスラエル - ヘブライ語 - Ministry of Health

אקסיטיניב טבע 3 מג

teva israel ltd - axitinib - טבליות מצופות פילם - axitinib 3 mg - axitinib

אקסיטיניב טבע  5 מג イスラエル - ヘブライ語 - Ministry of Health

אקסיטיניב טבע 5 מג

teva israel ltd - axitinib - טבליות מצופות פילם - axitinib 5 mg - axitinib

יירבוי 5 מגמל イスラエル - ヘブライ語 - Ministry of Health

יירבוי 5 מגמל

bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.

אפיניטור 5 מג イスラエル - ヘブライ語 - Ministry of Health

אפיניטור 5 מג

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 10 מג イスラエル - ヘブライ語 - Ministry of Health

אפיניטור 10 מג

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 2.5 מג イスラエル - ヘブライ語 - Ministry of Health

אפיניטור 2.5 מג

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אופדיבו イスラエル - ヘブライ語 - Ministry of Health

אופדיבו

bristol, myers squibb (israel) limited, israel - nivolumab - תרכיז להכנת תמיסה לאינפוזיה - nivolumab 10 mg/ml - nivolumab

טיסנטריק イスラエル - ヘブライ語 - Ministry of Health

טיסנטריק

roche pharmaceuticals (israel) ltd - atezolizumab - תרכיז להכנת תמיסה לאינפוזיה - atezolizumab 60 mg/ml

טיסנטריק イスラエル - ヘブライ語 - Ministry of Health

טיסנטריק

roche pharmaceuticals (israel) ltd - atezolizumab - תרכיז להכנת תמיסה לאינפוזיה - atezolizumab 60 mg / 1 ml

סירמזה 10 מגמל イスラエル - ヘブライ語 - Ministry of Health

סירמזה 10 מגמל

eli lilly israel ltd, israel - ramucirumab - תרכיז להכנת תמיסה לאינפוזיה - ramucirumab 10 mg/ml - ramucirumab